Example: barber

of the Patient

Dec 15, 2021 · The predominant feature of ET is thrombocytosis (increased platelet count). A Janus kinase 2 (JAK2) enzyme mutation, JAK2 3V617F, is present in approximately 50 -60% of patients living with ET.,4 Additionally, calreticulin (CALR) mutation is present in approximately 20 -25% of ET patients.4 Common

Tags:

  Thrombocytosis

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Advertisement

Related search queries